NEW YORK, May 10 – Visible Genetics of Toronto said Thursday its first quarter revenues slipped slightly to $3.57 million, compared with $3.64 million in the year ago period, as an increase in product sales failed to offset a sharp drop in revenues from services.

During the quarter, however, the clinical genomics company said sales of its genotyping kits and consumables rose 85 percent from the year ago quarter. The company did not offer a dollar figure for sales of these products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.